AN2 Therapeutics, Inc. Common Stock

Day range

$3.50 – $3.70

Open

$3.55

Prev close

$3.55

Volume

123.42K

Market cap

$133.96M

Shares out

37.74M

P/E

—

P/S

—

P/B

1.76

P/FCF

—

ROE

-47.8%

ROA

-44.4%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Clinical trial resultsJun 4, 2026

  The Phase 1 FIH study (NCT07024589) evaluated single ascending oral doses of AN2-502998 and then multiple ascending doses administered over 10 days in healthy adult volunteers: AN2-502998 was generally well tolerated with no dose-limiting toxicities. Human PK was well characterized; plasma exposures at or above NHP efficacy thresholds were achieved.

• Deal terminationApr 9, 2026

  Effective as of April 9, 2026, the Company terminated the Sales Agreement (the "TD Cowen Sales Agreement"), dated April 6, 2023, that the Company previously entered into with Cowen and Company, LLC, which was assigned to TD Securities (USA) LLC. Prior to the termination, the Company sold 2,502,000 shares of Common Stock having an aggregate offering price of $20,016,251 under the TD Cowen Sales Agreement.

• Executive compensation changeMar 20, 2026

  On March 19, 2026 (the "Repricing Date"), the Board of Directors of AN2 Therapeutics, Inc. approved a stock option repricing (the "Option Repricing"), effective as of the Repricing Date, of all outstanding stock options granted under the Plans prior to the Repricing Date. Pursuant to the Option Repricing, the exercise price of each Eligible Option was reduced to $3.91 per share, the closing price of the Company's common stock on the Repricing Date.

• Executive officer appointmentJan 29, 2026

  On January 26, 2026, the Board of Directors (the "Board") of AN2 Therapeutics, Inc. (the "Company") appointed Sarah Williams as Vice President, Controller and Principal Accounting Officer of the Company. Ms. Williams assumes the role (effective as of February 1, 2026).

• Investor presentationJun 11, 2025

  On June 11, 2025, AN2 Therapeutics, Inc. (the "Company") posted an updated investor presentation on the "Investors" section of its website, which is furnished as Exhibit 99.1 hereto and is incorporated by reference herein.

Days to cover

9.5

Short interest

2.49M

Avg volume

261.16K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Nontuberculous Mycobacterial Infections Market to Showcase Growth at a CAGR of 12.6% During the Forecast Period (2026–2036), Driven by Rising Disease Burden and Emerging Therapies | DelveInsight
  positiveGlobeNewswire Inc.· Aug 31, 2026
• Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround
  Zacks Investment Research· May 21, 2024
• ZoomInfo Technologies To Rally Around 50%? Here Are 10 Top Analyst Forecasts For Tuesday
  Benzinga· Feb 13, 2024
• Nasdaq Edges Lower; ContextLogic Shares Surge
  Benzinga· Feb 12, 2024
• Why Big Lots Shares Are Trading Lower By Around 31%? Here Are Other Stocks Moving In Monday's Mid-Day Session
  Benzinga· Feb 12, 2024